128 related articles for article (PubMed ID: 21427556)
1. Molecular markers of response to treatment for melanoma.
Sznol M
Cancer J; 2011; 17(2):127-33. PubMed ID: 21427556
[TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
3. New approaches in metastatic melanoma: biological and molecular targeted therapies.
Lejeune FJ; Rimoldi D; Speiser D
Expert Rev Anticancer Ther; 2007 May; 7(5):701-13. PubMed ID: 17492933
[TBL] [Abstract][Full Text] [Related]
4. New therapeutic targets in melanoma.
Martí RM; Sorolla A; Yeramian A
Actas Dermosifiliogr; 2012 Sep; 103(7):579-90. PubMed ID: 22261672
[TBL] [Abstract][Full Text] [Related]
5. Update on therapy for melanoma: opportunities for patient selection and overcoming tumor resistance.
Koon HB; Atkins MB
Expert Rev Anticancer Ther; 2007 Jan; 7(1):79-88. PubMed ID: 17187522
[TBL] [Abstract][Full Text] [Related]
6. Combination of targeted therapy and immunotherapy in melanoma.
Blank CU; Hooijkaas AI; Haanen JB; Schumacher TN
Cancer Immunol Immunother; 2011 Oct; 60(10):1359-71. PubMed ID: 21847631
[TBL] [Abstract][Full Text] [Related]
7. Molecular targets in melanoma from angiogenesis to apoptosis.
Sosman JA; Puzanov I
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2376s-2383s. PubMed ID: 16609062
[TBL] [Abstract][Full Text] [Related]
8. Systemic therapy for metastatic malignant melanoma--from deeply disappointing to bright future?
Lorigan P; Eisen T; Hauschild A
Exp Dermatol; 2008 May; 17(5):383-94. PubMed ID: 18312390
[TBL] [Abstract][Full Text] [Related]
9. Management of metastatic melanoma 2005.
O'Day S; Boasberg P
Surg Oncol Clin N Am; 2006 Apr; 15(2):419-37. PubMed ID: 16632224
[TBL] [Abstract][Full Text] [Related]
10. Prospects for non-immunological molecular therapeutics in melanoma.
Eustace AJ; Mahgoub T; Tryfonopoulos D; O'Donovan N; Crown J
J BUON; 2010; 15(1):9-18. PubMed ID: 20414921
[TBL] [Abstract][Full Text] [Related]
11. Melanoma: from darkness to promise.
Gasent Blesa JM; Grande Pulido E; Alberola Candel V; Provencio Pulla M
Am J Clin Oncol; 2011 Apr; 34(2):179-87. PubMed ID: 20498590
[TBL] [Abstract][Full Text] [Related]
12. Molecular predictors of response to chemotherapy in colorectal cancer.
Dienstmann R; Vilar E; Tabernero J
Cancer J; 2011; 17(2):114-26. PubMed ID: 21427555
[TBL] [Abstract][Full Text] [Related]
13. The Challenge of Developing New Therapies for Childhood Cancers.
Balis FM
Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
[TBL] [Abstract][Full Text] [Related]
14. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.
Andersen MH; Gehl J; Reker S; Pedersen LØ; Becker JC; Geertsen P; thor Straten P
Semin Cancer Biol; 2003 Dec; 13(6):449-59. PubMed ID: 15001164
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
[TBL] [Abstract][Full Text] [Related]
16. Predicting benefit from anti-angiogenic agents in malignancy.
Jubb AM; Oates AJ; Holden S; Koeppen H
Nat Rev Cancer; 2006 Aug; 6(8):626-35. PubMed ID: 16837971
[TBL] [Abstract][Full Text] [Related]
17. Cytokine-based therapy and biochemotherapy for advanced melanoma.
Atkins MB
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2353s-2358s. PubMed ID: 16609058
[TBL] [Abstract][Full Text] [Related]
18. Molecular predictors of response to antiangiogenesis therapies.
Gerger A; LaBonte M; Lenz HJ
Cancer J; 2011; 17(2):134-41. PubMed ID: 21427557
[TBL] [Abstract][Full Text] [Related]
19. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.
Le Tourneau C; Vidal L; Siu LL
Drug Resist Updat; 2008 Jun; 11(3):99-109. PubMed ID: 18515176
[TBL] [Abstract][Full Text] [Related]
20. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]